A new injectable version of the cancer drug pembrolizumab, known as Keytruda, begins rollout for patients in England and Wales this week. Northern Ireland patients cannot yet access the treatment. The Department of Health stated it is aware of the jab and exploring ways to provide it as soon as possible.

Prof Mark Lawler from Queen's University Belfast called the injectable form an important development in cancer treatment. He described it as a novel approach in immunotherapy, the biggest advance in the field in 25 years. The drug helps the immune system target cancer cells by blocking proteins that shield tumours.

Previously administered via intravenous drip taking over an hour, Keytruda will now be given as a one-minute injection every three weeks or a two-minute injection every six weeks, based on the patient's cancer type. Prof Lawler said this change benefits patients and the health system by reducing hospital time.

Prof Lawler urged equal access across the UK to avoid a postcode lottery. He noted colleagues in Scotland share frustration over the delay in Northern Ireland. He welcomed the Department of Health's efforts and offered assistance from the scientific community.

Prof Lawler suggested funding as a likely barrier but argued the injection saves time and costs, addressing waiting time complaints. He stressed capacity is not an issue since it shortens administration.